Developers want Hamilton mayor to help fast-track urban-expansion development
A consortium of developers hoping to expand Hamilton’s frozen urban boundary to build thousands of homes on farmland wants ...
Buffalo company tops growth charts, secures major funding
From topping regional growth charts to securing substantial funding, CleanFiber is on a roll. It is one of Business First's ...
The Herald Journal3d
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...
Insider Monkey on MSN13d
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer
Lantern Pharma Inc. (NASDAQ:LTRN) is an artificial intelligence (AI) company that develops precision oncology therapies. On ...
Yahoo Finance13d
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer
In this article, we are going to take a look at where Lantern Pharma Inc. (NASDAQ:LTRN) stands against the other AI stocks that broke the Internet recently. With Trump taking in the reigns soon ...
Taiwan News20h
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study ( NCT06617429 ...
Silicon Valley’s Secondary Markets Are Bigger Than Ever
Secondary transactions involving venture-backed startups are on track to hit a new high this year, as companies like OpenAI, ...
manilatimes2d
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
The Phase 1 trial is a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of oral SCY-247 in approximately 100 healthy subjects. The primary endpoint is safety ...
Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...
Stockhouse17d
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elritercept for very low-, low- and intermediate-risk MDS. MDS and MF are characterized by ...